摘要
目的:探讨大剂量沐舒坦对肺癌手术患者恢复的影响。方法:选取2010年3月-2012年3月在本院胸外科行手术治疗的138例肺癌患者为研究对象,应用随机数字表法将其分成对照组和观察组,每组各69例,对照组患者给予小剂量沐舒坦进行治疗,观察组给予大剂量沐舒坦进行治疗,两组患者其他治疗措施相同,比较对照组和观察组患者并发肺不张、肺部感染和急性呼吸衰竭的发生率。结果:观察组患者肺叶切除术后肺不张和肺部感染发生率明显低于对照组,差异有统计学意义(P<0.05),但是,两组急性呼吸衰竭差异无统计学意义(P>0.05),且对照组和观察组患者在不良反应发生率方面差异无统计学意义(P>0.05)。结论:大剂量沐舒坦静脉滴注能够明显减少肺不张、肺部感染和急性呼吸衰竭发生率。
Objective： To investigate the complications in patients with lung cancer after surgery by using larger dose of ambroxol.Method： The clinical data of one hundred and thirty-eight patients with lung cancer after surgery who were treated in our hospital from March 2010 to March 2012 were collected, then theY were divided into the control group（69 cases） and the observation group（69 cases） by using a random number table, patients in the control group was given small dose of ambroxol,but patients in the observation group was given larger dose of ambroxol, other measures of the two groups were the same, the pulmonary atelectasis, pulmonary infection and acute respiratory failure of two group was evaluated.Result： The incidence of the pulmonary atelectasis and pulmonary infection was lower in the observation group than that in the control group （P0.05）,and there were no statistical differences in the incidence of acute respiratory failure and adverse reaction （P0.05）.Conclusion： Continous intravenous pumping larger dose of ambroxol can into obtaine satisfactory curative effect, it can reduce the incidence of the pulmonary atelectasis, pulmonary infection and acute respiratory failure.
出处
《中国医学创新》
CAS
2013年第1期6-7,共2页
Medical Innovation of China
关键词
沐舒坦
肺癌
临床疗效
Ambroxol
Lung cancer
Clinical efficacy
